The aggressive low density lipoprotein lowering controversy (Q34058242)

30 July 2017

1 reference

title

The aggressive low density lipoprotein lowering controversy (English)

1 reference

30 July 2017

1 reference

Forrester JS

1

1 reference

30 July 2017

Bairey-Merz CN

series ordinal

2

1 reference

30 July 2017

Kaul S

series ordinal

3

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 October 2000

1 reference

Journal of the American College of Cardiology

30 July 2017

1 reference

30 July 2017

36

1 reference

30 July 2017

4

1 reference

30 July 2017

1419-1425

1 reference

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Statin trials and goals of cholesterol-lowering therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Range of serum cholesterol values in the population developing coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

On the relationship between cholesterol lowering and coronary disease event rate

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Serum cholesterol in young men and subsequent cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Changes in serum cholesterol level and mortality: a 30-year follow-up. The Finnish cohorts of the seven countries study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Lipid lowering versus revascularization: an idea whose time (for testing) has come

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Harvard Atherosclerosis Reversibility Project Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Lipid-lowering interventions in angiographic trials

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: new evidence, implications and outstanding issues.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Effects of lipid lowering therapy on progression of coronary and carotid artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Interrelations of lipids and lipoproteins with coronary artery disease mortality in 19 countries.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Direct vascular effects of HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Effects of lipids and lipoproteins on thrombosis and rheology.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Effect of pravastatin on outcomes after cardiac transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Is aggressive cholesterol control justified? Review of the post-coronary artery bypass graft trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Cholesterol reduction and clinical benefit. Are there limits to our expectations?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900829-9

7 January 2021

10.1016/S0735-1097(00)00829-9

Identifiers

DOI

1 reference

30 July 2017

1 reference